Conjugated cargo drug via covalent linkage

The term 'conjugated cargo drug via covalent linkage' refers to the therapeutic payload and its chemical attachment mechanism within a larger drug conjugate system, such as an antibody-drug conjugate (ADC) or peptide-drug conjugate (PDC) [1]. It is not a biological target (e.g., a receptor or enzyme) but rather a structural component of a delivery modality designed to transport potent pharmacological agents directly to diseased cells [2]. The cargo drug is typically a highly potent cytotoxic agent, such as a microtubule inhibitor or DNA-damaging agent, that would be too toxic for systemic administration on its own [3]. The covalent linkage is engineered to remain stable in systemic circulation and release the cargo specifically within the target environment, often through enzymatic cleavage or pH-dependent hydrolysis [2]. This approach enhances the therapeutic index by maximizing drug concentration at the site of action while minimizing exposure to healthy tissues [1]. Notable examples of such cargo drugs include monomethyl auristatin E (MMAE) and emtansine (DM1), which are used in several FDA-approved therapies [3]. Sources: [1] Sievers EL, Senter PD. Chem Rev. 2013; [2] Jain N, et al. Pharm Res. 2015; [3] Beck A, et al. Nat Rev Drug Discov. 2017.

Other names

Drug payloadEffector moleculeCytotoxic cargoDrug-linker conjugateADC payload

The conjugated cargo drug acts as the effector moiety that is delivered to a specific site (e.g., a tumor cell) via a targeting vehicle such as an antibody. Upon internalization or extracellular release, the covalent linkage is cleaved (or the conjugate is degraded), releasing the active drug to exert its pharmacological effect, such as inhibiting mitosis or damaging DNA [1, 2].